In recent years, a new class of cancer therapies known as antibody-drug conjugates (ADCs) has been gaining significant traction. These innovative therapies represent a smarter, more targeted approach to cancer treatment, combiningRead More…
The field of oncology has witnessed a paradigm shift in recent years with the rise of antibody-drug conjugates (ADCs). These sophisticated therapies combine the precision of monoclonal antibodies with the cytotoxic powerRead More…
In the ever-evolving landscape of oncology, the integration of targeted therapies and immunotherapy has emerged as a transformative strategy, particularly in breast cancer. Antibody-drug conjugates (ADCs), celebrated for their precision in deliveringRead More…
Antibody-Drug Conjugates (ADCs) have revolutionized cancer therapy by combining the precision of monoclonal antibodies with the potency of cytotoxic drugs. These “guided missiles” selectively deliver payloads to tumor cells, minimizing damage toRead More…
The field of antibody-drug conjugates (ADCs) is experiencing a major transformation due to the development of bispecific ADCs (BsADCs) that merge the dual-targeting functionality of bispecific antibodies (BsAbs) with the cell-killing powerRead More…
The cure of cancer is not the only goal on the table and the very best are antibody-drug conjugates. These innovative drugs combine monoclonal antibodies with cytotoxic chemotherapies to deliver highly targetedRead More…
In a new study, researchers from Yale School of Medicine hide tumor-fighting antibodies from cancer by disguising them in molecules that cancers use to nourish tumor growth, based on a new therapyRead More…
Researchers from the University of Basel in Switzerland published a research paper titled “Selective haematological cancer eradication with preserved haematopoiesis” in the journal Nature. The entire hematopoietic system can be reconstructed byRead More…
The emergence of antibody-drug conjugates (ADCs) as a potential cancer treatment pathway has attracted a great deal of attention. By combining the selective specificity of monoclonal antibodies with the cytotoxicity of drugRead More…
Conditionally activated antibody prodrug conjugate (PDC) Traditional ADCs not only target receptors expressed on tumor cells but also those on certain healthy tissues, leading to inevitable off-tumor toxicity. Probody Drug Conjugates (PDCs)Read More…